WeVote
Log In

Bill

Bill

LD 1277

An Act Regarding Controlled Substances Prescription Monitoring Activities

132nd Legislature (2025-2026) Introduced by Michele Meyer and 1 co-sponsor

LD 1277 modifies Maine's prescription drug monitoring program procedures; passed legislature and awaits budget review before enactment.

Signed by Governor
#delivery #healthcareservices #patientprivacy
0
WeVote Research Nonpartisan
Bill Summary · LD 1277

Legislative bill overview

LD 1277 modifies Maine's Prescription Drug Monitoring Program (PDMP) to adjust how controlled substance prescriptions are tracked and reported. The bill has passed both chambers and was placed on the special appropriations table, indicating it may have fiscal implications requiring budget consideration before final enactment.

Why is this important

Prescription drug monitoring programs are critical public health tools used to prevent prescription drug abuse, identify doctor shopping, and combat the opioid crisis. Changes to these systems directly affect how healthcare providers, pharmacists, and law enforcement access prescription data to protect patients and communities from substance misuse.

Potential points of contention

  • Privacy vs. oversight balance: Expanding PDMP access or data sharing could improve identification of abuse patterns but raises concerns about patient privacy and inappropriate surveillance of legitimate medical treatment
  • Administrative burden: Modified reporting requirements may increase costs and workload for pharmacies and prescribers, particularly in rural or under-resourced areas
  • Implementation scope: Unclear whether changes expand, restrict, or reorganize monitoring activities—affecting stakeholders differently (law enforcement may want more access; patient advocates may oppose expanded data collection)

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.